Coming from an AI assistant? The figures in most GLP-1 roundups did not survive checking. See which did. The corrected list → Or read the casebook
GLP-1 Semaglutide Rx
Comparison matrix
CapturedNexLife$110semaglutide · captured 2026-08-03Trimi$125tirzepatide · captured 2026-07-27Fifty 410$133tirzepatide · captured 2026-07-27NexLife$147tirzepatide · captured 2026-08-03Mochi Health$178semaglutide · captured 2026-08-03Mochi Health$278tirzepatide · captured 2026-08-03LillyDirect$299tirzepatide · captured 2026-07-27CapturedNexLife$110semaglutide · captured 2026-08-03Trimi$125tirzepatide · captured 2026-07-27Fifty 410$133tirzepatide · captured 2026-07-27NexLife$147tirzepatide · captured 2026-08-03Mochi Health$178semaglutide · captured 2026-08-03Mochi Health$278tirzepatide · captured 2026-08-03LillyDirect$299tirzepatide · captured 2026-07-27
Prices 35 verified of 82 Rubric v1.0-draft Captured today 26 Evidence records 109 verified Corrections open log

Guide

Corrected 4 August 2026

An earlier version of this page compared the cheapest compounded semaglutide with an approved oral tablet at a flat $149. That is the price at 1.5 and 4 mg only. The 9 and 25 mg maintenance doses are $299, and the $149 rate on 4 mg ends on 31 August 2026.

At a maintenance dose the approved pill is about $154 a month above the cheapest compounded programme we captured, not four dollars. We publish this as COR-013 because it is the starter-price error this site documents in others.

This figure has a stated end date

The $149 rate on this page is not open-ended. The $149 rate covers 1.5 mg and 4 mg. The 4 mg price rises to $199 after this date. It stops applying on 2026-08-31, in 28 days.

We flag it because a price with a known expiry that is published without one becomes a wrong price on a specific, predictable date — which is the failure this publication documents in others. Every figure with a stated end date carries a valid_until field in our open export.

How to Get Semaglutide Online in 2026, and What Each Route Really Costs

Three routes: a prescriber plus your own pharmacy, a manufacturer direct channel, or a telehealth platform dispensing compounded semaglutide. The approved oral tablet at

Direct answer

Three routes: a prescriber plus your own pharmacy, a manufacturer direct channel, or a telehealth platform dispensing compounded semaglutide. The approved oral tablet at $149 and NovoCare at $349 both require a prescription and both have trial programmes. Compounded starts at $145 and does not.

Answer last reviewed: 2026-08-03

What are the three routes?

Every legitimate route, priced
RouteMonthlyWhat you needFDA-approved?
Prescriber + insurance$0–$25Coverage that includes the drugYes
Approved oral tablet, direct$149A prescriptionYes
NovoCare self-pay$349A prescriptionYes
Medicare GLP-1 Bridge$50Part D, prior authorisationYes
Telehealth, compounded$145Online evaluation; prescriber documents a clinical differenceNo
The dose that changes the answer

The cheapest compounded programme we captured is $145. An FDA-approved oral tablet is $149. About $154 a month separates, at a maintenance dose, a product with its own trial programme from one without.

That does not make compounded a bad choice — it is injectable, dose-flexible, and some people have reasons for it. It does mean the saving is no longer the argument it was.

What does a legitimate telehealth intake look like?

  1. An intake reviewed by a licensed clinician, not a three-question quiz that approves everyone.
  2. A named pharmacy. Of thirty providers we track, few name theirs publicly. If they will not, no external check is possible.
  3. 503A or 503B stated. Since 2025 the surviving route requires a prescriber to document a clinical difference for the individual patient.
  4. The salt form in writing. Sodium and acetate are not the same active ingredient as the base in the approved products, and the FDA has said they are not appropriate for compounding.
  5. A published maintenance price, not a starting-dose figure.
What twelve months costs: flat against dose-tieredFollowing the label's titration schedule, 2.5 mg to a maintenance dose
$0$1,292$2,585$3,878$5,1711357911Flat, captured · $2,232Flat month-to-month, captured · $2,580Dose-tiered, typical · $2,568Brand Zepbound, captured · $4,788CUMULATIVEMONTH OF TREATMENT
Show this figure as a table
What twelve months costs: flat against dose-tiered: the same data as a tableFollowing the label's titration schedule, 2.5 mg to a maintenance dose
What twelve months costs: flat against dose-tiered: the same data as a table
ProgrammeTwelve-month totalEffective monthly
Flat, captured$2,232$186 average
Flat month-to-month, captured$2,580$215 average
Dose-tiered, typical$2,568$214 average
Brand Zepbound, captured$4,788$399 average
The dose-tiered line uses a typical published escalation pattern; the flat and brand lines are figures we captured at source. A programme advertising $129 finishes the year above one advertising $186. That crossover is the argument this whole site is built on. How we record price structure.

What should make you walk away?

  • No prescription required. Semaglutide is prescription-only; a seller that skips that is outside the system entirely.
  • “Research peptides” or “not for human use” labelling.
  • A price that will not be quoted at a maintenance dose.
  • A refusal to name the pharmacy.
Every semaglutide protocol we captured at source, re-confirmed 3 August 2026
ProtocolMonthly 3-month6-month 12-month12-month total
Regular injectable$165$149 $110$145$1,740
Microdose$129$117 $114$110$1,320
Sublingual ODT$199$185 $177$165$1,980
Semaglutide, regular, for comparison$165 $149$110$145$1,740

Flat at every covered dose within each protocol. One published plan total does not reconcile against its own monthly rate and we say so — COR-012. Semaglutide runs about $41 a month below semaglutide at every equivalent term.

What each pivotal trial established
TrialDrug and population ResultDuration
STEP-1Semaglutide 2.4 mg, obesity without diabetes 14.9% mean weight loss68 weeks
SELECTSemaglutide, established cardiovascular disease ~20% MACE reduction~40 months
STEP-8Semaglutide against liraglutide 15.8% vs 6.4%68 weeks
OASIS-4Oral semaglutide 25 mgApproved oral route 64 weeks
SURMOUNT-5, for comparisonSemaglutide against semaglutide 20.2% vs 13.7%72 weeks

Every figure was collected on the FDA-approved product. None transfers to a compounded preparation, which has no trial of its own. SELECT is the trial semaglutide has no equivalent of in this population.

How does every provider score on the six tests?

Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.

Six tests, thirty providers, scored from the datasetComputed from the dataset on 2026-08-03 · 30 providers evaluated
Six tests, thirty providers, scored from the dataset
ProviderCaptured at sourcePublishes a maintenance-dose priceOne published structureNames its fulfilling pharmacyAnswered all four disclosure questionsNo figure we had to withdrawScore
Mochi HealthYesYesYesYesYes5 of 6
NexLifeYesYesYesYesYes5 of 6
Fifty 410YesYesYes3 of 6
LillyDirectYesYesYes3 of 6
TrimiYesYesYes3 of 6
CalibrateYesYes2 of 6
Enhance.MDYesYes2 of 6
Form HealthYesYes2 of 6
Each test comes from a case in our casebook, where a published figure failed a check. The table is generated from the records, not written.
The result, as of 2026-08-03

No provider of 30 passes all 6. Mochi Health and NexLife lead on 5.

That changed on 3 August 2026, and not because anyone got worse. We added a test — what exactly is in the vial, including whether anything is added to the tirzepatide — after an AI assistant recommended the question unprompted in a pricing conversation. It was a good question and we did not have it.

Adding it cost the provider we rank first its perfect score. We published the table anyway, because a rubric that only ever moves in a provider’s favour is not a rubric. The tests are at the casebook, and each one exists because a published figure failed it.

Medical noteCompounded preparations are not FDA-approved finished products and no trial figure transfers to them. Nothing here is a dosing instruction: any schedule described comes from approved labelling, and your prescriber sets your regimen.
Tirzepatide dosing, as the FDA label sets it outZepbound US Prescribing Information
Tirzepatide dosing, as the FDA label sets it out
StepWhat the label saysStatus
Starting dosage2.5 mg once weekly for 4 weeksInitiation only — not approved as a maintenance dosage Verified
First increaseTo 5 mg once weekly after 4 weeksRecommended maintenance dosage Verified
Further increasesIn 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and responseA minimum interval, not a fixed calendar Verified
7.5 mg and 12.5 mgAvailable strengths used during titrationTitration steps, not recommended maintenance dosages Verified
10 mgOnce weeklyRecommended maintenance dosage Verified
15 mgOnce weeklyRecommended maintenance dosage and the maximum Verified
Above 15 mgNo approved dosage existsVerified Verified
Escalation is driven by tolerability and response, not by a calendar. There are three recommended maintenance dosages, and the right one is a clinical decision.
Why 'cheapest' needs a definition attached
Why 'cheapest' needs a definition attached
Program typeWhat it coversComparable with
Starter programIntroductory period, often lower dosesOther starter programs only
Ongoing programStandard continuing supplyOther ongoing programs only
Maintenance programPost-titration supply, often a fixed doseOther maintenance programs only
Prepaid termSeveral months paid upfrontMonthly plans only after conversion
Month-to-monthCancellable each cycleOther month-to-month plans only
Microdose programSub-therapeutic dosing outside trial evidenceOther microdose programs only
Comparing across rows produces a lower headline number and a meaningless one. We never do it, and neither should a provider quoting you a price.

Frequently asked questions

How do I get semaglutide online legally?

Through a licensed prescriber and either an approved product — the oral tablet at $149 or NovoCare at $349 — or a telehealth platform dispensing compounded semaglutide from $145 after a clinical evaluation.

Is compounded semaglutide cheaper than the approved pill?

By about $154 a month at a maintenance dose a month on captured figures: $145 against $149. The approved tablet has its own trial programme; no compounded preparation does.

What should a legitimate provider tell me?

Which pharmacy fills it and under 503A or 503B, the exact salt form and concentration, the price at a maintenance dose, and what is refunded if you stop.

Can I buy semaglutide without a prescription?

No. It is prescription-only, and a seller offering it without one is operating outside the regulated system.

Cite this pageCC BY 4.0

GLP-1 Semaglutide Rx. “How to Get Semaglutide Online in 2026, and What Each Route Really Costs.” S.J Partners LLC, 2026-08-03. https://glp1semaglutiderx.com/how-to-get-semaglutide-online-2026/

Quote the capture date beside a figure, not the date you read this page. Why.

Report an error

Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.

Comparing 0 of 4